Search research articles
Contact Us
Filters
Showing results (51-60 of 143) with videos related to
Page
of 15
Sort By:
JCO Clinical Cancer Informatics
|
January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug Development
Joyce F Liu, Jung-Min Lee, Ellie Strock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2013
Developing standards for breakthrough therapy designation in oncology
Sandra J Horning, Daniel A Haber, Wendy K D Selig, et al.
Oncotarget
|
February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
David M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
The Oncologist
|
March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Joseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies
Shivaani Kummar, Larry Anderson, Kimberly Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group
Lia Gore, S Percy Ivy, Frank M Balis, et al.
Cancer
|
February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
Alexander Drilon, Anne A Eaton, Katja Schindler, et al.
Frontiers in Oncology
|
May 25, 2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors
Aman Chauhan, Elise C Kohn, S Percy Ivy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
Julie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Anne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Page
of 15
Search research articles
Search
Showing results (51-60 of 143) with videos related to
Sort By:
Page
of 15
JCO Clinical Cancer Informatics
|
January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug Development
Joyce F Liu, Jung-Min Lee, Ellie Strock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2013
Developing standards for breakthrough therapy designation in oncology
Sandra J Horning, Daniel A Haber, Wendy K D Selig, et al.
Oncotarget
|
February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
David M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
The Oncologist
|
March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Joseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies
Shivaani Kummar, Larry Anderson, Kimberly Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group
Lia Gore, S Percy Ivy, Frank M Balis, et al.
Cancer
|
February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
Alexander Drilon, Anne A Eaton, Katja Schindler, et al.
Frontiers in Oncology
|
May 25, 2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors
Aman Chauhan, Elise C Kohn, S Percy Ivy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
Julie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Anne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Page
of 15